• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Mar­ket­ingRx roundup: Mod­er­na clues in to ‘Jeop­ardy’; BMS, Gilead build out clin­i­cal tri­al di­ver­si­ty pro­gram

3 years ago
Pharma
Marketing

Bet­ting on CD47 as oth­ers ditch the tar­get, ALX bor­rows up to $100M to push sole clin­i­cal drug for­ward

3 years ago
Financing
R&D

Covid-19 con­tin­ues to be­fud­dle Big Phar­ma as Ab­b­Vie ax­es PhI of an oral drug

3 years ago
R&D
Coronavirus

Up­dat­ed: Sam­sara backs ex-Gilead duo's amal­ga­ma­tion of NASH, liv­er drug as­sets from for­mer em­ploy­er, oth­er bio­phar­mas

3 years ago
Financing
Startups

Up­dat­ed: Eli Lil­ly blames Biden's IRA for can­cer drug dis­con­tin­u­a­tion as the new phar­ma play­book takes shape

3 years ago
R&D
FDA+

JP Mor­gan splash­es in­to the life sci­ences, tap­ping Stephen Squin­to to run ven­ture team with high-pow­ered ad­vi­sors

3 years ago
Deals
Bioregnum

Covid-19 spurred a his­toric vac­cine R&D ef­fort. What does it mean for fu­ture pan­demics?

3 years ago
R&D
Coronavirus

Pfiz­er de­clares 'first-ever' PhI­II win for RSV vac­cine in in­fants — and it's steer­ing straight to FDA

3 years ago
R&D

A sin­gle in­jec­tion of Uni­ty's an­ti-ag­ing hy­poth­e­sis bears fruit in PhII, as piv­otal plans shape up

3 years ago
R&D

Drew Arm­strong is com­ing to End­points(!) And there are some more sur­pris­es to come

3 years ago
Bioregnum

That se­cre­tive ARCH biotech with two an­ti­bod­ies from Mor­phoSys? It’s now got $120M

3 years ago
Financing
Startups

#CPHI22: End­points sits down with con­fer­ence ex­ec as the man­u­fac­tur­ing world says ‘Guten Tag’ to CPHI

3 years ago
Manufacturing

#CPHI22: Con­tract man­u­fac­tur­ers will still be nav­i­gat­ing glob­al chal­lenges in­to next year

3 years ago
Outsourcing
Manufacturing

#CPHI22: An­nu­al re­port shows ‘mod­er­ate out­look’ and fo­cus on mR­NA

3 years ago
Manufacturing

#CPHI22: A look back at the biggest man­u­fac­tur­ing projects in 2022

3 years ago
Manufacturing

#CPHI22: Cell and gene man­u­fac­tur­ing ex­pect­ed to see a bump as it moves out of the pan­dem­ic

3 years ago
R&D

#CPHI22: Sup­ply chain woes are still bear­ing down on man­u­fac­tur­ers

3 years ago
Manufacturing

Bris­tol My­er­s' block­buster-to-be Re­blozyl scores a PhI­II win

3 years ago
Pharma

Dai­ichi Sankyo sets new highs for As­traZeneca-part­nered can­cer drug En­her­tu

3 years ago
Pharma

FDA to kick off CMC readi­ness pi­lot pro­gram next April

3 years ago
Pharma
FDA+

Ab­b­Vie puts up fight against Orilis­sa gener­ics from San­doz, Te­va and oth­ers

3 years ago
Pharma
Law

Un­der hub-and-spoke biotech, se­r­i­al founders launch new start­up hop­ing to make gene ther­a­pies for the eye

3 years ago
Startups
Cell/Gene Tx

Ther­mo Fish­er wa­gers on ear­ly can­cer di­ag­nos­tics in $2.6B cash deal for mul­ti­ple myelo­ma test mak­er

3 years ago
Deals
Diagnostics

In­trin­sic want­ed an IPO. In­stead, it's a SPAC for the gut-brain mi­cro­bio­me biotech

3 years ago
Financing
Startups
First page Previous page 430431432433434435436 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times